Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Andrologia ; 50(1)2018 Feb.
Article in English | MEDLINE | ID: mdl-28261848

ABSTRACT

Previous studies have investigated whether physical activity increases serotonin hormone levels. Serotonin receptor dysfunction is one of the frequently accused factors of premature ejaculation (PE). Nevertheless, no studies up to date have demonstrated that the association between physical activity and premature ejaculation. We aimed to investigate the relationship between physical activity and PE and determine whether moderate physical activity might delay ejaculation time or be an alternative treatment for PE. A total of 105 patients diagnosed with PE were enrolled in this study. Of the patients, 35 were treated with dapoxetine, (30 mg) on demand (Group 1), 35 performed moderate physical activities (Group 2), and 35 performed minimal physical activity (Group 3-sham). Demographic characteristics, metabolic equivalents (MET), premature ejaculation diagnostic tool (PEDT) and intravaginal ejaculatory latency time (IELT) were recorded. There were no significant differences among three groups in terms of age, BMI, MET, PEDT or IELT before treatment. At the end of the study, there was significant decrease in PEDT scores, and increase in IELT in groups 1 and 2 as compared to Group 3. In conclusion, a moderate physical activity longer than 30 min at least 5 times a week leads to ejaculation delay, and appears as an alternative to dapoxetine on demand for the treatment of PE.


Subject(s)
Benzylamines/therapeutic use , Exercise Therapy/methods , Exercise/physiology , Naphthalenes/therapeutic use , Premature Ejaculation/therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adolescent , Adult , Benzylamines/pharmacology , Ejaculation/drug effects , Ejaculation/physiology , Humans , Male , Middle Aged , Naphthalenes/pharmacology , Premature Ejaculation/drug therapy , Premature Ejaculation/physiopathology , Prospective Studies , Self Report , Selective Serotonin Reuptake Inhibitors/pharmacology , Young Adult
2.
Eur Rev Med Pharmacol Sci ; 19(18): 3528-35, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26439053

ABSTRACT

OBJECTIVE: Ureteral obstruction leads to permanent changes in the structure of the kidney by several mechanisms. In this study, it was hypothesized that there would be a protective effect of misoprostol against diclofenac in rats with unilateral ureteral obstruction (UUO). MATERIALS AND METHODS: Twenty-two female rats were randomized into 5 groups of 4 and 2 rats for the control group. The right ureter was sutured. The rats were grouped as control, contrast agent, contrast agent +N-acetylcysteine (NAC),  diclofenac and diclofenac + misoprostol groups.Radiographic contrast agent was given iv on the 3rd day and other agents were administered orally for 1 week. The rats were sacrified after 1 week and histopathological and biochemical oxidative stress markers were evaluated. RESULTS: The contrast agent and NAC  group  had lower rates of hemorrhage, inflammation, obstructive dilatation and fatty degeneration compared to the contrast agent only group (p < 0.05). No differences were seen in the normal kidneys. Between all the groups, there was no difference for tubule epithelium damage (p > 0.05). The contrast agent and NAC group had higher rates of antioxidant SH level compared to the contrast agent only group (p < 0.05) and lower rates of oxidative end product carbonyl groups (p < 0.05). For normal kidneys no difference was seen. No statistical difference was seen in MDA levels (p > 0.05). Statistically no difference was seen between the diclofenac group and the diclofenac and misoprostol group neither pathologically nor chemically (p > 0.05). CONCLUSIONS: These results showed that NAC is protective against radiographic contrast agent toxicity when given before and after administration in obstructed kidneys as in previous data. Misoprostol was not observed to have any protective effect against diclofenac in obstructed kidneys.


Subject(s)
Diclofenac/adverse effects , Kidney/drug effects , Misoprostol/therapeutic use , Ureteral Obstruction/physiopathology , Administration, Oral , Animals , Disease Models, Animal , Female , Kidney/pathology , Misoprostol/administration & dosage , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...